This HTML5 document contains 39 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n8http://linked.opendata.cz/resource/drugbank/drug/DB05830/identifier/chemspider/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/drugbank/drug/DB05830/identifier/wikipedia/
n12http://bio2rdf.org/drugbank:
n6http://linked.opendata.cz/resource/drugbank/drug/DB05830/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/drug/DB05830/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05830
rdf:type
n3:Drug
n3:description
Trestolone (7α-methyl-19-nortestosterone) is a synthetic androgen developed by the Population Council as a potential candidate drug for use in hormonal male contraceptive methods. In males, regular administration of sufficient quantities of trestolone induces a state of temporary infertility.
n3:generalReferences
# Walton MJ, Kumar N, Baird DT, Ludlow H, Anderson RA: 7alpha-methyl-19-nortestosterone (MENT) vs testosterone in combination with etonogestrel implants for spermatogenic suppression in healthy men. J Androl. 2007 Sep-Oct;28(5):679-88. Epub 2007 Apr 25. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17460095 # Ramachandra SG, Ramesh V, Krishnamurthy HN, Kumar N, Sundaram K, Hardy MP, Rao AJ: Effect of chronic administration of 7alpha-methyl-19-nortestosterone on serum testosterone, number of spermatozoa and fertility in adult male bonnet monkeys (Macaca radiata). Reproduction. 2002 Aug;124(2):301-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12141943
n3:group
investigational
n3:indication
Investigated for use/treatment in contraception and male hormonal deficiencies/abnormalities.
owl:sameAs
n12:DB05830
dcterms:title
7a-methyl-19-nortestosterone
adms:identifier
n6:19582 n7:MENT n8:18447 n9:DB05830
n3:mechanismOfAction
Spermatozoa are produced in the testes of males in a process called spermatogenesis. In order to render a man infertile, a hormone-based male contraceptive method must stop spermatogenesis by interrupting the release of gonadotropins from the pituitary gland. Even in low concetrations, trestolone is a potent inhibitor of the release of the gonadotropin hormones, luteinizing hormone (LH) and follicle stimulating hormone (FSH). In order for spermatogenesis to occur in the testes, both FSH and the male hormone testosterone must be present. By inhibiting release of FSH, trestolone creates an endocrine environment in which conditions for spermatogenesis are not ideal. Manufacture of sperm is further impaired by the suppression of LH, which in turn drastically cutails the production of testosterone. Sufficient regular doses of trestolone cause severe oligozoospermia or azoospermia, and therefore infertility, in most male patients.
n3:IUPAC-Name
n4:271B477E-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4784-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4783-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4780-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4781-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4782-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B477C-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B477A-363D-11E5-9242-09173F13E4C5 n4:271B477D-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B477B-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B478A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B478B-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4785-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4786-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4788-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4787-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4789-363D-11E5-9242-09173F13E4C5
n3:category
n3:Bioavailability
n4:271B4790-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4792-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4793-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B478F-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B478E-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4791-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B477F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B478C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B478D-363D-11E5-9242-09173F13E4C5